ArticleDermatology and therapy2025

Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study.

Yukari Okubo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.